High Court Won't Hear Apotex's Risperdal Appeal

Law360, New York (March 23, 2009, 12:00 AM EDT) -- Apotex Inc. has lost its bid to have the nation's highest court revive its counterclaims of noninfringement in connection with a patent fight over Johnson & Johnson subsidiary Janssen Pharmaceutica NV's anti-psychotic drug Risperdal.

The U.S. Supreme Court on Monday shot down Apotex's petition for a writ of certiorari, giving no reason for its decision. The Canadian pharmaceutical maker had appealed to the high court in January after the U.S. Court of Appeals for the Federal Circuit in September upheld a district judge's decision to dismiss...
To view the full article, register now.